Bilateral ureteral obstruction (BUO) is associated with marked changes in the expression of renal aquaporins (AQPs) and sodium transport proteins. To examine the role of prostaglandin in this response, we investigated whether 24-h BUO changed the expression of cyclooxygenases (COX-1 and -2) in the kidney and tested the effect of the selective COX-2 inhibitor parecoxib (5 mg ⅐ kg Ϫ1 ⅐ day
via osmotic minipumps) on AQPs and sodium transport. Sham and BUO kidneys were analyzed by semiquantitative immunoblotting, and a subset of kidneys was perfusion fixed for immunocytochemistry. BUO caused a significant 14-fold induction of inner medullary COX-2 (14.40 Ϯ 1.8 vs. 1.0 Ϯ 0.4, n ϭ 6; P Ͻ 0.0001) and a reduction in medullary tissue osmolality, whereas COX-1 did not change. Immunohistochemistry confirmed increased COX-2 labeling associated with medullary interstitial cells. COX isoforms did not change in cortex/outer medulla after 24-h BUO. In BUO kidneys, inner medullary AQP2 expression was reduced, and this decrease was prevented by parecoxib. In the inner stripe of outer medulla, the type 3 Na ϩ /H ϩ exchanger (NHE3) and apical Na ϩ -K ϩ -2Cl Ϫ cotransporter (BSC-1) were significantly reduced by BUO, and this decrease was significantly attenuated by parecoxib. Immunohistochemistry for AQP2, NHE3, and BSC-1 confirmed the effect of parecoxib. Parecoxib had no significant effect on the Na-K-ATPase ␣1-subunit, type II Na-Pi cotransporter, or AQP3. In conclusion, acute BUO leads to marked upregulation of COX-2 in inner medulla and selective COX-2 inhibition prevents dysregulation of AQP2, BSC-1, and NHE3 in response to BUO. These data indicate that COX-2 may be an important factor contributing to the impaired renal water and sodium handling in response to BUO. cyclooxygenase; PGE2; parecoxib; AQP2 BILATERAL URETERAL OBSTRUCTION (BUO) is a serious clinical condition, which occurs in both children and adults. In children, BUO is usually caused by congenital abnormalities of the kidneys and urinary tract whereas some of the most common explanations among adults are stones, benign enlargement of the prostate, and neoplasms of the urinary tract.
BUO is associated with an increased intraluminal pressure in the ureter, pelvis, and renal tubules and the acute consequence is anuria. Obstruction is associated with ischemia and after relief of an obstruction there is reperfusion, which is associated with parenchymal and functional injury of the kidneys (26) . There are extensive changes in the systemic water and sodium balance due to the impaired ability to concentrate urine (5) . The pathophysiology behind the loss of the urinary concentrating ability is complex and involves all nephron segments. Recent studies have demonstrated that aquaporins (AQP1-4), the water channels located at the proximal tubule, descending thin limb, and collecting duct, and major renal sodium transporters located along all renal nephron segments, were significantly reduced during and after BUO or unilateral ureteral obstruction (UUO) (15, 16, 25, 28 -30) . These findings suggested that reduced expression of the renal aquaporins and sodium transporters contributed to the impairment in urinary concentrating capacity and salt wasting in response to urinary tract obstruction. The mechanisms responsible for the dysregulation of these transport proteins and channels remain incompletely understood.
The mammalian kidney is one of the most active prostaglandin (PG)-producing tissues, and PGE 2 is the quantitatively dominant prostanoid. PGE 2 regulates and modulates renal hemodynamics and tubular water and salt transport (19) . Cyclooxygenase (COX) is the major rate-limiting enzyme in the cascade leading to synthesis of PG from arachidonic acid. Two isoforms of COX have been identified, namely, COX-1 and COX-2. The COX-1 isoform is believed to be constitutively expressed in most cells and thought to be involved in the maintenance of various physiological functions (39) , whereas COX-2 is undetectable in most tissues. In contrast, COX-2 is constitutively expressed in the kidney (18) . In kidney cortex, COX-2 is expressed in the thick ascending limb (TAL) (6, 14) and macula densa whereas in the medulla, COX-2 is found in medullary interstitial cells (48) . COX-2 expression is differentially regulated by salt intake in the kidney zones; dietary salt depletion stimulates COX-2 expression in the cortex, and vice versa in the renal medulla (23, 47) . In the renal medulla, COX-2 is enhanced by dehydration and AVP infusion (46) . BUO for 24 h enhances prostaglandin production in cortical and medullary tubules of the rat kidney (45) , and increased COX-2 expression has been observed in the obstructed kidney in response to both 24-h UUO (8) , ureteral obstruction of a solitary kidney (37) , and in response to BUO followed by release (7) . Importantly, it was demonstrated that administra-tion of a COX-2 inhibitor reduced tissue transforming growth factor-␤, resulting in decreased renal tubular damage and interstitial fibrosis in UUO (33) . Moreover, it was recently demonstrated that COX-2 inhibition of rats with a solitary obstructed kidney prevented macrophage infiltration in the interstitium of kidneys 24 h after release of the obstruction (37) . Thus there is solid experimental evidence that COX activity is enhanced after obstruction.
The role of PGE 2 in vasopressin-mediated water permeability is not fully understood. Recent studies have demonstrated that PGE 2 does not affect directly cAMP levels but may have post-cAMP effects rather than actions via cAMP regulation (35) . It has been suggested that PGE 2 on the basolateral side stimulates calcium mobilization (10, 37) . Moreover, recent studies have shown the effect of PGE 2 on PKA phosphorylation of AQP2 in kidney papilla associated with retrieval of AQP2 from the plasma membrane but that this appears to be independent of AQP2 phosphorylation by PKA (36, 49) . Importantly, it was recently demonstrated that COX-2 inhibition attenuated the polyuria in rats subjected to 24-h BUO followed by release and that this was associated with prevention of AQP2 downregulation in the obstructed kidney (7) .
The apparent parallel stimulation of renal COX activity and downregulation of key transport molecules by BUO led us to hypothesize a causal relationship between these events. In the present study, our aim was to examine 1) whether BUO for 24 h is associated with changes in the localization and abundance of cyclooxygenases in kidney, and 2) whether selective COX-2 inhibition during BUO is associated with changes in the expression of both renal aquaporins and key renal sodium transport proteins.
METHODS
Experimental animals. All procedures conformed with the Danish national guidelines for the care and handling of animals and to the published guidelines from the National Institutes of Health. The animal protocols were approved by the board of the Institute of Clinical Medicine, University of Aarhus, according to the licenses for use of experimental animals issued by the Danish Ministry of Justice. Studies were performed in male Munich-Wistar rats initially weighing 200 g (Møllegaard Breeding Centre, Eiby, Denmark). The rats had free access to a standard rodent diet (Altromin, Lage, Germany) and tapwater. During the experiments rats were kept in individual metabolic cages, with a 12:12-h light-dark cycle, a temperature of 21 Ϯ 2°C, and humidity of 55 Ϯ 2%. Rats were allowed to acclimatize to the cages 3-4 days before surgery. The rats were placed on anesthesia with isoflurane (Abbott Scandinavia), and during the operation the rats were placed on a heating pad to maintain rectal temperature at 37-38°C. Through a midline abdominal incision, both ureters were exposed and then occluded with a 5-0 silk ligature.
Rats were allocated to the protocols indicated below. Age-and time-matched, sham-operated controls were prepared and were observed in parallel with each BUO group in the following protocols. Protocol 1. BUO was induced for 24 h (n ϭ 10). The kidneys were prepared for semiquantitative immunoblotting (n ϭ 6) or for immunocytochemistry (n ϭ 4). Next, sham-operated controls were prepared in parallel (n ϭ 9), and the kidneys were prepared for semiquantitative immunoblotting (n ϭ 6) or for immunocytochemistry (n ϭ 3).
Protocol 2. BUO was induced for 24 h. In group 1 (n ϭ 6), osmotic minipumps (Alzet, Scanbur, Denmark) with saline were surgically implanted subcutaneously (n ϭ 6). In group 2 (n ϭ 6), osmotic minipumps (Alzet) with parecoxib (Pfizer) dissolved in saline (40 mg/ml) were surgically implanted subcutaneously and the dose was given at a rate of 5 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 during the 24 h of obstruction. Next, sham-operated rats were operated on in parallel. In group 3 (n ϭ 6), osmotic minipumps with saline were implanted subcutaneously. In group 4 (n ϭ 6), osmotic minipumps (Alzet) with parecoxib (Pfizer) dissolved in saline (40 mg/ml) were surgically implanted subcutaneously and the dose was given at a rate of 5 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 during the 24-h control period. Administration of 5 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 parecoxib was chosen according to the pharmacological profile of parecoxib previously demonstrated (38) .
Blood sampling and removal of kidneys. Twenty-four hours after induction of BUO, rats were reanesthetized with isoflurane. Before death, the aortic bifurcation of the rat was localized, dissected free, and a 5-to 7-ml blood sample was collected for the determination of plasma electrolytes, hormones, and osmolality. Rapidly, the kidneys were removed and dissected into cortex and outer stripe of outer medulla (OM), inner stripe of outer medulla (ISOM), and inner medulla (IM). The plasma concentrations of sodium, potassium, creatinine, and urea were measured (Vitros 950, Johnson & Johnson). The plasma concentration of aldosterone was determined by radioimmunoassay (Active Aldosterone Ria Kit, DSL 8600 Diagnostic System Laboratories, Webster, TX). Plasma renin concentration (PRC) was measured by ultramicroassay of generated ANG I using renin standards as described (31) . Five serial dilutions from the same plasma sample were assayed in duplicate for all samples. Only when at least three of the dilutions were linear was the measurement accepted. Renin concentration is expressed in Goldblatt units (GU) compared with renin standards from the National Institute for Biological Standards and Control (Hertfordshire, UK). Finally, osmolality of the plasma was determined with a vapor pressure osmometer (Osmomat 030, Gonotec, Berlin, Germany).
PGE 2 measurements in the urine after release of obstruction. To examine the inhibitory effect of parecoxib on prostaglandin production, we performed 24-h BUO followed by release for 24 h with collection of urine. In group 1 (n ϭ 6), osmotic minipumps with saline were implanted subcutaneously. In group 2 (n ϭ 6), osmotic minipumps with parecoxib dissolved in saline (40 mg/ml) were implanted and the dose was given at a rate of 5 mg ⅐ kg Ϫ1 ⅐ day
Ϫ1
during a period of 48 h. Next, sham-operated rats were operated on in parallel. In group 3 (n ϭ 6), osmotic minipumps with saline were implanted subcutaneously. Urine was collected, and PGE 2 excretion was measured after 24-h release. A commercial enzyme immunoassay kit (Amersham Pharmacia Biotech, Little Chalfont, UK) was used to determine PGE 2 in the urine. Measurement of IM osmolality. Kidneys were rapidly removed, and the whole IM was excised on ice from each kidney and weighed. One-half of the IM was thoroughly homogenized with a motor-driven homogenizer, after addition of 300 l of distilled water. Homogenate osmolality was determined with a vapor pressure osmometer (Osmomat 030, Gonotec).
IM osmolality was calculated, assuming that 80% of IM wet weight is water (2). Quantitative PCR. For quantitative PCR, 100 ng cDNA served as a template for PCR amplification using iQ SYBR-Green supermix according to the manufacturer's instructions (Bio-Rad). Serial dilution (1 ng-1 fg/l) of plasmid prRenin with exons 1 and 2 inserted in the polylinker site was used as a template for generation of a standard curve. Nested primers were used to amplify standards and kidney cDNA samples (sense CAG ACA CAG CCA GCT TTG; antisense CCA TTC AGC ACT GAT CCT; GenBank accession no. NM012642, covering bases 71-174, 104 bp). Standards and unknown samples were amplified in duplicate in 96-well plates, and PCR was performed for 43 cycles consisting of denaturation for 30 s at 95°C followed by annealing and polymerization at 58°C for 45 s. Emitted fluorescence was detected during the annealing/extension step in each cycle. Specificity was assured by postrun melting curve analysis and by agarose gel electrophoresis.
Membrane fractionation for immunoblotting. The tissue (cortexϩOM, ISOM, and IM) was homogenized in dissecting buffer (0.3 M sucrose, 25 mM imidazole, 1 mM EDTA, pH 7.2) containing the following protease inhibitors: 8.5 M leupeptin (serine and cysteine protease inhibitor, Sigma), and 0.4 mM pefabloc (serinprotease inhibitor, Roche). Moreover, the dissecting buffer for IM was added following phosphatase inhibitors Na ϩ -orthovanadate (Sigma), Na-F (Merck), and okadic acid (Calbiochem). The tissue was homogenized for 30 s of 1,250 s by an Ultra-Turrax T8 homogenizer (IKA Labortechnik) and then centrifuged 4,500 g at 4°C for 15 min. Gel samples were prepared from the supernatant in Laemmli sample buffer containing 2% SDS. The total protein concentration of the homogenate was measured using a Pierce BCA protein assay kit (Roche).
Electrophoresis and immunoblotting. Samples of membrane fractionation from the three different zones were run on 12% polyacrylamide minigels (Bio-Rad Mini Protean II). For each gel, an identical gel was run in parallel and subjected to Coomassie staining. The Coomassie-stained gel was applied to determine identical loading or to allow for correction for minor variations in loading.
Samples were run on 9, 10, and 12% polyacrylamide gels (Bio-Rad Protean II). Proteins were transferred to a nitrocellulose membrane (Hybond ECL RPN 3032D, Amersham Pharmacia Biotech). Afterward, the blots were blocked with 5% nonfat dry milk in PBS-T (80 mM Na 2HPO4, 20 mM NaH2PO4, 100 mM NaCl, 0.1 Tween 20, adjusted to pH 7.4). After being washed with PBS-T, the blots were incubated with primary antibodies overnight at 4°C. The antigenantibody complex was visualized with horseradish peroxidase-conjugated secondary antibodies (P448, diluted 1:3,000, DAKO, Glostrup, Denmark) using the enhanced chemiluminiscence system (Amersham Pharmacia Biotech). Immunolabeling controls were performed using a peptide-absorbed antibody.
Primary antibodies. For semiquantitative immunoblotting and immunocytochemistry, we used previously characterized monoclonal and polyclonal antibodies as summarized below.
COX-1 (Cayman Chemical, Ann Arbor, MI, catalog no. 160109): an affinity-purified rabbit polyclonal antibody against COX-1. Fig. 1 . Semiquantitative immunoblots of cyclooxygenase COX-1 and COX-2 using kidney protein isolated from cortex and outer stripe of outer medulla (CϩOSOM) from sham-operated (SHAM) and bilateral ureteral obstructed (BUO) rats. A total of 50 g protein was used for the COX-1 and COX-2 assay. A: immunoblot was reacted with anti-COX-1 antibody and revealed a single ϳ71-kDa band. B: densitometric analyses of all the samples from sham-operated and obstructed kidneys of rats with 24-h BUO revealed that there was no difference between control and obstructed kidneys (96 Ϯ 8 vs. 100 Ϯ 8%). C: immunoblot was reacted with anti-COX-2 antibody and revealed a single ϳ72-kDa band. D: densitometric analyses of all the samples from sham-operated and obstructed kidneys of rats with 24-h BUO revealed that there was no difference between control and obstructed kidneys (91 Ϯ 12 vs. 100 Ϯ 18%). Fig. 2 . Semiquantitative immunoblots of COX-1 and COX-2 using kidney protein isolated from inner medulla (IM) from sham-operated (SHAM) and BUO rats. A total of 20 g protein was used for the COX-1 assay, and 10 g were used for the COX-2 assay. A: immunoblot was reacted with anti-COX-1 antibody and revealed a single ϳ71-kDa band. B: densitometric analyses of all the samples from shamoperated and obstructed kidneys of rats with 24-h BUO revealed that there was no difference between control and obstructed kidneys (102 Ϯ 17 vs. 100 Ϯ 6%). C: immunoblot was reacted with anti-COX-2 antibody and revealed a single ϳ72-kDa band. D: densitometric analyses of all the samples from sham-operated and obstructed kidneys of rats with 24-h BUO revealed that there was a marked increase in the COX-2 expression in the obstructed kidneys compared with the sham-operated rats (1,946 Ϯ 359 vs. 100 Ϯ 4%). *P Ͻ 0.05. COX-2 (Cayman Chemical, catalog no. 160126): an affinity-purified rabbit polyclonal antibody against COX-2. AQP2 (LL127 serum or LL127AP): immune serum or an affinitypurified antibody to AQP-2 has previously been described (9) . AQP3 (LL178AP): an affinity-purified polyclonal antibody to AQP3 has previously been described (10) . Type 3 Na ϩ /H ϩ exchanger (NHE3; LL546AP): an affinity-purified polyclonal antibody to NHE3 has previously been described (12) .
The type II Na-Pi cotransporter (NaPi2; LL697AP/LL696AP): affinity-purified polyclonal antibody to NaPi2 has previously been described (3) .
Na-K-ATPase: a monoclonal antibody against the ␣1-subunit of Na-K-ATPase has previously been described (24) .
The apical Na ϩ -K ϩ -2Cl Ϫ cotransporter (BSC1; LL320AP): an affinity-purified polyclonal antibody to the apical Na-K-2Cl cotransporter of the TAL has previously been described (11) .
Immunocytochemistry. The kidneys from BUO rats and shamoperated control rats were fixed by retrograde perfusion via the abdominal aorta with 3% paraformaldehyde in 0.1 M cacodylate buffer, pH 7.4. Moreover, the kidneys were immersion fixed for 1 h and washed 3 ϫ 10 min with 0.1 M cacodylate buffer. The kidney blocks were dehydrated and embedded in paraffin. The paraffinembedded tissues were cut in 2-m sections on a rotary microtome (Leica Microsystems, Herlev, Denmark).
For immunoperoxidase labeling, the sections were deparaffinized and rehydrated. Endogenous peroxidase activity was blocked with 5% H2O2 in absolute methanol for 10 min at room temperature. To expose antigens, kidney sections were boiled in a target retrieval solution (1 mmol/l Tris, pH 9.0, with 0.5 mM EGTA) for 10 min. After cooling, nonspecific binding was prevented by incubating the sections in 50 mM NH 4Cl in PBS for 30 min, followed by blocking in PBS containing 1% BSA, 0.05% saponin, and 0.2% gelatin. Sections were incubated with primary antibodies diluted in PBS with 0.1% BSA and 0.3% Triton X-100 overnight at 4°C. After being washed 3 ϫ 10 min with PBS supplemented with 0.1% BSA, 0.05% saponin, and 0.2% gelatin, the sections were incubated with horseradish peroxidaseconjugated secondary antibody (P448, goat anti-rabbit immunoglobulin, DAKO) for 1 h at room temperature. After being rinsed with PBS wash buffer, the sites of antibody-antigen reactions were visualized with 0.05% 3,3Ј-diaminobenzidine tetrachloride (Kem-en Tek, Copenhagen, Denmark) dissolved in distilled water with 0.1% H 2O2. Light microscopy was carried out with a Lecia DMRE (Leica Microsystem).
Statistics. Values are presented as means Ϯ SE. Statistical comparisons between experimental groups were made by a standard unpaired t-test or one-way ANOVA with Bonferroni correction. P values Ͻ0.05 were considered significant.
RESULTS

Impaired renal function after 24-h BUO.
BUO was induced by occlusion of both ureters and after 24 h the rats were killed and blood samples were collected and analyzed. Rats with 24-h BUO exhibited a significant increase in the plasma concentration of creatinine, urea, potassium, and osmolality compared with sham-operated rats, consistent with impaired renal function (Table 1) . Plasma aldosterone levels were significantly increased compared with sham-operated controls (Table 1) . This is consistent with previous observations in rats subjected to 24-h BUO (29) .
Increased renal IM COX-2 expression in response to 24-h BUO.
To test whether the expression of COX-1 and COX-2 was altered after 24 h of BUO, semiquantitative immunoblotting of samples from cortexϩOM and IM were performed for the COX-1 and -2 isoforms as well as for actin. The abundance of COX-1 (Fig. 1, A and B) and COX-2 (Fig. 1, C and D) protein in cortexϩOM was unchanged after 24-h BUO. The abundance of COX-1 in IM was unchanged in BUO rats (Fig. 2, A and B) . In contrast, the abundance of COX-2 protein was significantly increased in IM after 24 h of BUO (Fig. 2, C and D) .
Immunohistochemical staining of kidney IM sections revealed that COX-2 immunoreactive protein was localized to the medullary interstitial cells in the papillary tip with no apparent difference between sham (Fig. 3, E and F) and BUO rats (Fig. 3, G and H) . However, there was a marked increase in the COX-2 labeling of IM interstitial cells at the base of the IM in BUO rats (Fig. 3, C and D) compared with shamoperated control rats (Fig. 3, A and B) . Thus BUO resulted in recruitment of COX-2-positive cells along the corticomedullary axis. In the cortex, COX-2-immunoreactive protein was detected at the macula densa region in kidneys from both obstructed and sham-operated control rats, and in the obstructed kidneys COX-2 labeling intensity and distribution ) or saline was administrated in osmotic minipumps during both the obstructed and release period. Each bar represents the mean Ϯ SE of 6 determinations. *P Ͻ 0.05 BUO compared with sham rats.
# P Ͻ 0.05 parecoxib-treated BUO compared with untreated 24-h BUO rats. were comparable to that seen in sham-operated control rats (not shown).
Immunostaining for COX-1 demonstrated an immunopositive signal from IM collecting duct cells and from interstitial cells (not shown). COX-1 immunolabeling in cortex and OM showed that COX-1 was localized to the connecting tubule and cortical collecting ducts (not shown). Furthermore, COX-1 also labeled the glomerular mesangial cells (not shown), as previously described (6) . COX-1 labeling in IM and cortexϩOM did not differ between the BUO rats and sham-operated control rats.
Effect of the COX-2 inhibitor parecoxib on urinary PGE 2 excretion. We examined the effect of parecoxib (dynastat; 5 mg/kg 24 h), a selective COX-2 inhibitor, on urinary PGE 2 excretion induced by BUO for 24 h. After release of BUO, PGE 2 excretion in urine was significantly stimulated (1.5 Ϯ 0.2 vs. 2.9 Ϯ 0.6 ng⅐min Ϫ1 ⅐day
Ϫ1
, P Ͻ 0.05, Fig. 4 ). The augmented PGE 2 excretion was abolished by parecoxib (2.9 Ϯ 0.6 vs. 1.4 Ϯ 0.2 ng⅐min Ϫ1 ⅐day
, P Ͻ 0.05, Fig. 4 ), demonstrating that COX-2 was the dominant source of PGE 2 synthesis.
Effect of COX-2 inhibition on kidney weight, plasma electrolytes, creatinine, and hormone levels in rats with 24-h BUO.
In protocol 2, the effect of a selective COX-2 inhibitor, parecoxib (5 mg⅐kg Ϫ1 ⅐day Ϫ1 ), was examined. BUO and sham rats were treated with parecoxib during the entire 24-h obstruction period. There was no significant difference between the untreated and treated sham-operated control rats with regard to body weight, kidney weight, plasma osmolality, and the plasma concentration of sodium, potassium, creatinine, and urea (Table 2 ). Similar to the results of protocol 1, plasma osmolality, potassium, creatinine, and urea increased significantly in the BUO rats compared with untreated control rats ( Table 2) . Parecoxib treatment partially inhibited the increase in kidney weight-to-body weight ratio and plasma urea in response to BUO (Table 2) . Moreover, the medullary tissue osmolality was significantly decreased in BUO rats compared with sham-operated control rats, and parecoxib had no effect on this parameter (Fig. 5 ). Plasma renin (Fig. 6B ) and aldosterone (Fig. 6C ) concentrations diverged as a result of BUO. Similar to the results of protocol 1, plasma aldosterone concentration was markedly elevated in parallel with plasma potassium concentration (Table 2) , whereas plasma renin concentration was strongly suppressed (Fig. 6B) . Consistent with this, renal cortical renin mRNA level was decreased in BUO rats (Fig. 6C) . Parecoxib treatment suppressed basal plasma renin and aldosterone concentrations in sham rats (Fig. 6 , B and C), whereas parecoxib had no effect on plasma concentrations in the BUO rats (Fig. 6, B and C) . Similarly, parecoxib treatment did not affect the renal renin mRNA level (Fig. 6A) . (Fig. 7, C and D) compared with sham-operated control rats (Fig. 7, A and B) . At the tip of the IM, there was no difference in COX-2 labeling between BUO and sham-operated rats. However, parecoxib treatment markedly enhanced COX-2 labeling in the IM of BUO kidneys, and COX-2 labeling was present in the entire IM from the base to the tip (Fig. 7, E and F) . In the ISOM, there was no labeling (Fig. 7G) .
COX-2 inhibition increased COX-2 expression in renal IM
Consistent with the results from protocol 1, COX-1 expression in IM from BUO rats was unchanged and maintained at the levels found in control rats (Table 3) . Parecoxib treatment did not change renal COX-1 expression in BUO rats (Table 3) .
COX-2 inhibition prevents downregulation of AQP2 expression in response to BUO. AQP2 is localized to the apical plasma membrane and subapical vesicles of the collecting duct principal cells. Consistent with previous studies, we confirmed that AQP2 expression in IM collecting ducts of BUO rats was markedly reduced compared with sham-operated control rats (arbitrary units: 2.0 Ϯ 0.2 vs. 5.1 Ϯ 0.3, P Ͻ 0.05) (Fig. 8B) . Parecoxib treatment prevented the BUO-induced reduction in AQP2 expression (4.6 Ϯ 0.5 vs. 5.1 Ϯ 0.3, not significant) (Fig. 8B) . These findings were confirmed by immunohistochemical analyses. In kidneys from sham-operated control rats, immunoperoxidase microscopy demonstrated that AQP2 labeling was localized in the apical domains of the IM collecting duct principal cells (Fig. 8C) . In kidneys from BUO rats, AQP2 labeling was much weaker in the apical plasma membrane domains of the IM collecting duct principal cells (Fig. 8D ) compared with sham-operated control rats. In the obstructed kidneys of parecoxib-treated BUO rats, AQP2 labeling was comparable to that seen in sham-operated control rats (Fig. 8E) .
AQP3 is localized to the basolateral plasma membranes of the collecting duct principal cells. Consistent with previous studies, we confirmed that AQP3 abundance decreased in IM collecting ducts of BUO rats compared with sham-operated control rats (arbitrary units: 2.8 Ϯ 1.0 vs. 4.5 Ϯ 0.4, P Ͻ 0.05) ( Table 3 ). In contrast to AQP2, parecoxib administration did not change AQP3 abundance in BUO rats compared with untreated BUO rats (5.4 Ϯ 1.3 vs. 2.8 Ϯ 1.0, Table 3) .
COX-2 inhibition attenuates downregulation of renal major sodium-transport proteins in response to BUO. We examined the effect of parecoxib on the expression of renal medullary sodium transporters and cotransporters in response to 24-h BUO. NHE3 was significantly decreased in the cortex and OM (Fig. 9B) . Consistent with this, immunohistochemistry showed weak labeling of NHE3 in the apical membranes of proximal tubule cells in the cortex (Fig. 9D ) and in Values are means Ϯ SE. n, No. of rats. COX-1, cyclooxygenase 1; COX-2, cyclooxygenase 2; AQP2, aquaporin 2; AQP3, aquaporin 3; NHE3, type 3 Na ϩ /H ϩ exchanger; BSC-1, rat type 1 bumetanide-sensitive cotransporter; NaPi, type II Na-Pi cotransporter; Na-K-ATPase, sodium-potassium-adenosine triphosphatase transporter; IM, inner medulla; ISOM, inner stripe of outer medulla; CORϩOM, cortexϩouter medulla. *P Ͻ 0.05 BUO compared with Sham. †P Ͻ 0.05 untreated BUO compared with parecoxib-treated BUO. Fig. 8 . Semiquantitative immunoblot of AQP2 using protein isolated from IM from sham-operated, parecoxib-treated sham-operated, 24-h BUO, and parecoxib-treated 24-h BUO rats. A: immunoblot was reacted with affinity-purified anti-AQP2 antibody and revealed a 29-kDa and 35-to 45-kDa bands, representing nonglycosylated and glycosylated forms of AQP2. B: densitometric analyses revealed that AQP2 expression in IM was marked decreased in the BUO rats compared with sham-operated control rats. Parecoxib treatment of BUO rats prevented this decrease in AQP2 expression, which was comparable to the control kidney. There was no difference between the untreated and parecoxibtreated control rats. *P Ͻ 0.05 BUO compared with sham-operated rats. # P Ͻ 0.05 parecoxibtreated BUO compared with untreated 24-h BUO rats. C: in sham-operated control rats, immunoperoxidase microscopy demonstrated that AQP2 labeling was associated with apical plasma membrane of principal cells in collecting ducts in the IM. D: in the obstructed kidney of BUO rats, reduced labeling for AQP2 was detected. E: the obstructed kidney from parecoxibtreated rats displayed labeling comparable to that seen in sham-operated rats.
the apical plasma membrane domains of medullary TAL and thin limb (Fig. 9G) of ISOM in BUO compared with shamoperated controls (Fig. 9, C and F) . In the BUO rats treated with parecoxib, the reduction in NHE3 labeling was attenuated compared with vehicle-treated BUO rats (Fig. 9, E and H) .
BSC-1 is mainly responsible for the apical sodium reabsorption in the cortical and medullary TAL. Semiquantitative immunoblotting from the ISOM revealed that the expression of BSC-1 was reduced after 24-h BUO compared with sham operated control rats (1.5 Ϯ 0.4 vs. 7.6 Ϯ 0.8, P Ͻ 0.05) (Fig.  10B) . Parecoxib treatment of BUO rats resulted in a significant attenuation of BSC-1 downregulation in ISOM (3.7 Ϯ 0.4 vs. 7.6 Ϯ 0.8, P Ͻ 0.05) (Fig. 10B) . Immunoperoxidase microscopy of kidney cortex, OM, and ISOM demonstrated that BSC-1 staining was associated with the apical plasma membrane domains of cortical (Fig. 10C ) and medullary TAL (Fig.  10F ) in sham-operated rats. In BUO kidneys, the labeling of BSC-1 in cortical and medullary TAL was much weaker (Fig.  10, D and G) , whereas in parecoxib-treated BUO rats BSC-1 labeling (Fig. 10, E and H) was comparable to sham-operated rats, demonstrating a marked parecoxib-induced prevention of BSC-1 downregulation in response to 24-h BUO.
DISCUSSION
The main results of the present study were that COX-2, and not COX-1, was markedly and selectively upregulated in IM interstitial cells in response to 24-h BUO despite a significant decrease in medullary tissue osmolality. The abundance of aquaporins AQP2 and AQP3 and sodium transporters NHE-3, BSC-1, and NaPi2 was reduced in response to BUO. Administration of the selective COX-2 inhibitor parecoxib to BUO rats inhibited the increase in PGE 2 excretion after release and prevented the downregulation of AQP2 and NHE3 and attenuated BSC-1 decrease. Basal plasma concentration of renin and aldosterone was suppressed by parecoxib in sham rats. BUO led to divergent, parecoxib-insensitive effects on renin and aldosterone. Fig. 9 . Semiquantitative immunoblot of NHE3 using protein isolated from C ϩ OSOM and ISOM from sham-operated, parecoxib-treated sham-operated, 24-h BUO, and parecoxib-treated 24-h BUO rats. A: immunoblot was reacted with anti-type 3 Na ϩ /H ϩ exchanger (NHE3) antibody and revealed a single 87-kDa band. B: densitometric analyses revealed that NHE3 expression in CORϩOM was marked decreased in the BUO rats compared with sham-operated control rats. Parecoxib treatment of BUO rats prevented this decrease in NHE3 expression, which was comparable to that in the control kidney. There was no difference between the untreated and parecoxibtreated control rats. *P Ͻ 0.05 BUO compared with sham-operated rats.
# P Ͻ 0.05 parecoxibtreated BUO compared with untreated 24-h BUO rats. Immunohistochemistry for NHE3 in COR and ISOM of sham-operated (C and F), 24-h BUO (D and G), and parecoxib-treated 24-h BUO (E and H) rats is shown. C and G: in sham-operated control rats, immunoperoxidase microscopy demonstrated that NHE3 labeling was associated with apical domains of proximal tubule (PT) cells and thick ascending limb (TAL) of the loop of Henle. D and H: in the obstructed kidney of BUO rats, reduced labeling of NHE3 was detected. E and H: obstructed kidney from parecoxib-treated rats shows labeling comparable to that seen in shamoperated rats.
Increased IM COX-2 expression in response to BUO.
The present study demonstrated an increased COX-2 expression in the IM in response to 24-h BUO. This is consistent with previous reports demonstrating an increase in IM COX-2 expression in response to BUO (7) , in response to occlusion of a solitary kidney (37) , and also in kidney IM of rats subjected to UUO (8) . This finding supports the view that COX-2 activity is responsible for the reported increase in renal PGE 2 and thromboxane A 2 synthesis in UUO (44) . Immunohistochemical staining demonstrated that COX-2 was selectively induced in the medullary interstitial cells of BUO kidneys. This is consistent with the results of previous studies demonstrating IM COX-2 expression localized to the interstitial cells of normal kidneys (17, 20, 42) . Several conditions induce COX-2 expression, including dehydration (46), AVP (50) , and NaCl loading (22) in the IM. Characteristically, these stimuli probably all converge on an increased interstitial osmolality, which is consistent with the observation that COX-2 is induced in cultured interstitial cells by increasing the osmolality of the medium (34) . In the present study, IM tissue osmolality decreased in response to 24 h of BUO. Thus it is unlikely that the BUO-induced enhanced medullary COX-2 expression was caused by changes in osmolality. The mechanisms involved in the medullary COX-2 induction in response to 24 h of BUO were not directly addressed in the present study, but several possibilities exist. During the first 24 h after onset of obstruction, the pressure in the urinary tract is highly elevated and this pressure increase may mechanically stimulate interstitial cells and induce increased COX-2 expression. Consistent with this, it was recently demonstrated that mechanical stretch can stimulate COX-2 in the bladder and vasculature (40) . Increased COX-2 expression in the IM may also result from inflammatory mediators in the kidney. Consistent with this, previous studies have shown that UUO led to an intense infiltration of inflammatory cells in the renal interstitium (41) .
Selective COX-2 inhibition prevents AQP2, NHE3, and BSC-1 downregulation. Our data documented that COX-2 activity contributed importantly to the alterations in water and Na transport proteins in response to 24-h BUO. Thus the well-known downregulation of renal AQPs and several key sodium transport proteins, previously demonstrated in response to BUO (28, 30) , was significantly weakened or prevented by administration of the selective COX-2 inhibitor parecoxib. This finding is consistent with the results of a recent study demonstrating that COX-2 inhibition prevented downregulation of AQP2 after release of 24 h Fig. 10 . Semiquantitative immunoblot of the type 1 bumetanide-sensitive Na-K-2Cl cotransporter (BSC-1) using protein isolated from inner stripe of outer medulla from sham-operated, parecoxib-treated sham-operated, 24-h BUO, and parecoxib-treated 24-h BUO rats. A: immunoblot was reacted with affinity-purified anti-BSC-1 antibody and revealed a strong, broad band of molecular mass (146 -176 kDa centered at 161 kDa). B: densitometric analyses revealed that BSC-1 expression in inner stripe of outer medulla was markedly decreased in the BUO rats compared with sham-operated control rats. Parecoxib treatment of obstructed kidneys from BUO rats did not significantly change BSC-1 expression compared with untreated BUO rats. There was no difference between the untreated and parecoxibtreated control rats. *P Ͻ 0.05 BUO compared with sham-operated rats. #P Ͻ 0.05 parecoxibtreated BUO compared with untreated BUO rats. Immunohistochemistry for BSC-1 in kidney cortex and inner stripe of outer medulla of shamoperated (C and F), 24-h BUO (D and G) and parecoxib-treated 24-h BUO (E and H) rats is shown. C and F: in sham-operated control rats, immunoperoxidase microscopy demonstrated that BSC-1 labeling was associated with the apical plasma membrane domains of cortical TAL cells and macula densa cells in the cortex and medullary TAL cells in the inner stripe of outer medulla. D and G: in the obstructed kidney of BUO rats, reduced labeling of BSC-1 was detected. E: in the obstructed kidney from parecoxib-treated rats, there was no difference in labeling intensity of BSC-1 in cortex. H: in the inner stripe of the outer medulla, the reduction in BSC-1 labeling of BUO rats was attenuated by parecoxib treatment.
of BUO in rats (7) . Recently, it was also demonstrated that administration of a COX-2 inhibitor reduced tissue transforming growth factor-␤, resulting in decreased renal tubular damage and interstitial fibrosis in UUO (33) , supporting the view that COX-2 inhibition has a beneficial effect on renal function in conditions with urinary tract obstruction. Consistent with this, it was recently demonstrated that COX-2 inhibition in rats with obstruction of a solitary kidney prevented the interstitial migration of macrophages known to be associated with enhanced cytokine release (39) . In the present study, parecoxib administration normalized urinary excretion of PGE 2 significantly just after release, which documents effective inhibition of COX-2 and suggests that COX-2 is the dominant source of PGE 2 synthesis. Parecoxib did not modify tissue osmolality, which indicated that the effect of COX-2 inhibition on the transport proteins was not mediated indirectly by a change in osmolality. The prevention of the increase in normalized kidney weight after parecoxib treatment indicates that COX-2 activity contributes to the marked swelling of the obstructed kidney.
Not all investigated proteins were equally sensitive to obstruction and/or parecoxib. Thus COX-1 and Na-K-ATPase did not change during the conditions tested, which documents that the observed BUO-induced changes were specific and not related to widespread necrosis or unspecific proteasomal degradation of all proteins. The differential effects of parecoxib on transporters could be related to the localization of the changes in COX-2 activity. Because prostanoids have a short range of action in vivo, PG-mediated effects related to BUO-induced COX-2 activity would be expected to prevail adjacent to the enzyme in the IM and OM. Consistent with this, AQP2, NHE3, and BSC-1 are found in these regions.
How are the effects of COX-2 activity mediated? PGE 2 is the major prostanoid synthesized in the kidney, and direct effects of PGE 2 on tubular epithelium are mediated by at least four distinct receptors with different intracellular coupling (4). In the TAL, PGE 2 inhibits reabsorption of NaCl through interaction with the Gi-coupled EP3 receptor (43) , and nonselective cyclooxygenase inhibitors such as indomethacin and diclofenac increase the abundance of BSC-1 and thereby enhance the active NaCl absorption in TAL (13) .
Furthermore, abluminal addition of PGE 2 inhibits the AVPinduced increase in water permeability in collecting ducts, probably mediated by the calcium-coupled EP1 receptor (1). PGE 2 has been shown to have no effect on the cAMP-induced water permeability of rat terminal IM collecting duct (35) and to counteract vasopressin-induced AQP2 translocation to the plasma membrane in slices of IM independently of dephosphorylation (49) .
Effect of COX-2 inhibition on hormone levels in rats with 24-h BUO. The data indicated that basal COX-2 activity supported renin secretion from the kidneys and thereby also plasma aldosterone. It is generally believed that the reninangiotensin-aldosterone system is activated by ureteral obstruction. We detected a strong inhibition of renin secretion and renin expression after obstruction, whereas aldosterone was markedly stimulated. Each of these changes was insensitive to COX-2 inhibition. Because plasma potassium was strongly elevated, this parameter was the factor most likely responsible for stimulating the adrenals to release aldosterone independently of renin-mediated angiotensin formation. The suppression of renin release and mRNA could be mediated by the BUO-associated rise in arterial blood pressure. Moreover, increased pressure in the absence of stretch inhibits renin secretion from isolated cells in vitro, and interstitial pressure rises sharply upon introduction of BUO (21) . In the present study, cortical COX-2 expression did not change in response to BUO, which indicated that the macula densa signal was less likely to play a major role in this setting. COX-2 can change rapidly (30 min) at this site in response to macula densamediated signals, e.g., furosemide or renal arterial stenosis (32) , and in a previous study where rats were subjected to 24 h of UUO COX-2 expression decreased in the cortex of the obstructed kidney compared with the contralateral kidney (8) . However, this model with one unobstructed, hyperfunctioning kidney is not directly comparable to the present model of BUO. The data emphasize that the acute phase of bilateral obstruction is characterized by suppression of renin and, most likely, also angiotensin. This suppression could contribute to downregulation of certain Na transporters, because we have previously shown a stimulation of transporter abundance in response to ANG II (27) .
Summary. The present study demonstrated that BUO in rats is associated with induction of COX-2 expression in the renal IM, which is localized to interstitial cells. Consistent with previous studies, BUO is associated with severe downregulation of renal aquaporins and key renal sodium transporters. Importantly, selective COX-2 inhibition prevents downregulation of renal IM AQP2 expression and attenuates downregulation of NHE3 and BSC-1 expression at the medullary TAL. Thus the present data suggest that increased PGE 2 synthesis in response to urinary tract obstruction may play an important role in the dysregulation of renal aquaporins and sodium transporters, which are crucial for the impaired urinary concentration capacity in obstructive nephrogenic diabetes insipidus.
